Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 375702, 9 pages
http://dx.doi.org/10.1155/2014/375702
Research Article

Clinical Value of Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Levels in Term Neonates with Infection or Sepsis: A Prospective Study

1Neonatal Unit, First Department of Pediatrics, Athens University Medical School, “Aghia Sophia” Children’s Hospital, 115 27 Athens, Greece
2Department of Clinical Biochemistry, “Aghia Sophia” Children’s Hospital, 115 27 Athens, Greece
3Department of Microbiology, “Aghia Sophia” Children’s Hospital, 115 27 Athens, Greece
4Hematology Laboratory, “Aghia Sophia” Children’s Hospital, 115 27 Athens, Greece

Received 4 January 2014; Accepted 8 April 2014; Published 5 May 2014

Academic Editor: Luca Cantarini

Copyright © 2014 Tania Siahanidou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Mussap, A. Noto, F. Cibecchini, and V. Fanos, “The importance of biomarkers in neonatology,” Seminars in Fetal & Neonatal Medicine, vol. 18, no. 1, pp. 56–64, 2013. View at Publisher · View at Google Scholar
  2. P. C. Ng and H. S. Lam, “Biomarkers for late-onset neonatal sepsis: cytokines and beyond,” Clinics in Perinatology, vol. 37, no. 3, pp. 599–610, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Thunø, B. MacHo, and J. Eugen-Olsen, “SuPAR: the molecular crystal ball,” Disease Markers, vol. 27, no. 3-4, pp. 157–172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Tzanakaki, M. Paparoupa, M. Kyprianou, A. Barbouni, J. Eugen-Olsen, and J. Kourea-Kremastinou, “Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 31, no. 6, pp. 1157–1162, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. C. R. Franco Palacios, J. C. Lieske, H. M. Wadei et al., “Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates,” Transplantation, vol. 96, pp. 394–399, 2013. View at Google Scholar
  6. K. Donadello, S. Scolletta, C. Covajes, and J.-L. Vincent, “SuPAR as a prognostic biomarker in sepsis,” BMC Medicine, vol. 10, article 2, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Kofoed, O. Andersen, G. Kronborg et al., “Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study,” Critical Care, vol. 11, article R38, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Koch, S. Voigt, C. Kruschinski et al., “Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients,” Critical Care, vol. 15, article R63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Backes, K. F. van der Sluijs, D. P. Mackie et al., “Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review,” Intensive Care Medicine, vol. 38, no. 9, pp. 1418–1428, 2012. View at Publisher · View at Google Scholar
  10. S. F. Kingsmore, N. Kennedy, H. L. Halliday et al., “Identification of diagnostic biomarkers for infection in premature neonates,” Molecular and Cellular Proteomics, vol. 7, no. 10, pp. 1863–1875, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Goldstein, B. Giroir, and A. Randolph, “International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics,” Pediatric Critical Care Medicine, vol. 6, no. 1, pp. 2–8, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Perch, P. E. Kofoed, T. K. Fischer et al., “Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection,” Parasite Immunology, vol. 26, no. 5, pp. 207–211, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Wrotek, K. Pawlik, and T. Jackowska, “Soluble receptor for urokinase plasminogen activator in community-acquired pneumonia in children,” in Neurobiology of Respiration, vol. 788 of Advances in Experimental Medicine and Biology, pp. 329–334, 2013. View at Publisher · View at Google Scholar
  14. P. Wittenhagen, J. B. Andersen, A. Hansen et al., “Plasma soluble urokinase plasminogen activator receptor in children with urinary tract infection,” Biomarker Insights, vol. 6, pp. 79–82, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Hoenigl, R. B. Raggam, J. Wagner et al., “Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome,” Clinical Biochemistry, vol. 46, no. 3, pp. 225–229, 2013. View at Publisher · View at Google Scholar
  16. K. Donadello, S. Scolletta, F. S. Taccone et al., “Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients,” Journal of Critical Care, vol. 29, no. 1, pp. 144–149, 2014. View at Publisher · View at Google Scholar
  17. B. Suberviola, A. Castellanos-Ortega, A. Ruiz Ruiz, M. Lopez-Hoyos, and M. Santibanez, “Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission,” Intensive Care Medicine, vol. 39, no. 11, pp. 1945–1952, 2013. View at Publisher · View at Google Scholar
  18. R. Uusitalo-Seppala, R. Huttunen, M. Tarkka et al., “Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study,” Journal of Internal Medicine, vol. 272, no. 3, pp. 247–256, 2012. View at Publisher · View at Google Scholar
  19. E. J. Giamarellos-Bourboulis, A. Norrby-Teglund, V. Mylona et al., “Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor,” Critical Care, vol. 16, no. 4, article R149, 2012. View at Google Scholar
  20. M. Dajak, S. Ignjatović, N. Majkić-Singh, Ž. Laušević, and V. Bukumirović, “Prognostic value of phospholipase A2 group II, C-reactive protein and simplified acute physiological score II in intensive care patients,” Clinical Laboratory, vol. 52, no. 7-8, pp. 387–392, 2006. View at Google Scholar · View at Scopus
  21. A. A. Adly, E. A. Ismail, N. G. Andrawes, and M. A. El-Saadany, “Circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as diagnostic and prognostic marker in neonatal sepsis,” Cytokine, vol. 65, no. 2, pp. 184–191, 2013. View at Publisher · View at Google Scholar
  22. O. Andersen, J. Eugen-Olsen, K. Kofoed, J. Iversen, and S. B. Haugaard, “Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy,” Journal of Medical Virology, vol. 80, no. 2, pp. 209–216, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. R. W. Stephens, A. N. Pedersen, H. J. Nielsen et al., “ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients,” Clinical Chemistry, vol. 43, no. 10, pp. 1868–1876, 1997. View at Google Scholar · View at Scopus
  24. R. Huttunen, J. Syrjänen, R. Vuento et al., “Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study,” Journal of Internal Medicine, vol. 270, no. 1, pp. 32–40, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. W. J. Wiersinga, L. M. Kager, J. W. R. Hovius et al., “Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis,” The Journal of Immunology, vol. 184, no. 6, pp. 3079–3086, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. A. W. Rijneveld, M. Levi, S. Florquin, P. Speelman, P. Carmeliet, and T. Van der Poll, “Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia,” The Journal of Immunology, vol. 168, no. 7, pp. 3507–3511, 2002. View at Google Scholar · View at Scopus
  27. C. Wei, S. El Hindi, J. Li et al., “Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis,” Nature Medicine, vol. 17, no. 8, pp. 952–960, 2011. View at Publisher · View at Google Scholar · View at Scopus